Ronald Beebe, MD
Allergy & Immunology · Gainesville, GANPI 1760445852
Payments from drug & device makers
Across 667 payments — averaging $83.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$29K
- AstraZeneca$17K
- Sanofi$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- CSL Behring$768
- Grifols USA, LLC$676
- plus $5K from 30 others
What the payments were for
- Consulting fees$450%
- Speaking & faculty fees$40,75073%
- Travel & lodging$6471%
- Food & beverage$14,34326%
- Education$1970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 100 | $28,846 |
| AstraZeneca | 126 | $17,379 |
| Sanofi | 65 | $1,651 |
| Takeda Pharmaceuticals U.S.A., Inc. | 69 | $1,539 |
| CSL Behring | 31 | $768 |
| Grifols USA, LLC | 32 | $676 |
| Regeneron Healthcare Solutions, Inc. | 31 | $610 |
| Biocryst US Sales Co., LLC | 26 | $606 |
| Mylan Specialty L.p. | 33 | $600 |
| Pfizer | 29 | $576 |
| Amgen | 20 | $472 |
| Teva Pharmaceuticals USA, Inc. | 16 | $302 |
| Novartis | 14 | $297 |
| Optinose US, Inc. | 10 | $174 |
| Octapharma USA, Inc. | 5 | $172 |
| Sanofi-aventis U.S. LLC | 2 | $157 |
| Eyevance Pharmaceuticals LLC | 8 | $155 |
| Hikma Pharmaceuticals USA | 7 | $133 |
| Pharming Healthcare, Inc. | 5 | $113 |
| Boehringer Ingelheim | 6 | $106 |
| Ionis Pharmaceuticals, Inc. | 4 | $84 |
| Aimmune Therapeutics, Inc. | 3 | $73 |
| ADMA Biomanufacturing LLC | 3 | $61 |
| Shire North American Group Inc | 3 | $57 |
| Bio Products Laboratory USA, Inc. | 3 | $53 |
| Cycle Pharmaceuticals Inc | 2 | $49 |
| AbbVie | 2 | $44 |
| Merck | 2 | $36 |
| Alk-abello, Inc | 2 | $31 |
| Kaleo, Inc. | 2 | $30 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $30 |
| Galderma Laboratories, L.p. | 1 | $25 |
| Viatris Specialty LLC | 1 | $21 |
| Verona Pharma, Inc. | 1 | $20 |
| Phadia US Inc. | 1 | $20 |
| LEO Pharma Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$27,334
- TEZSPIRE$14,744
- FASENRA$251
- DUPIXENT$223
How this compares
$55,983 in reported general payments places this provider in the 85th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 291 | $220,917 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 26 | $152,741 |
| Dupixent SyringeDupilumab | 37 | $138,541 |
| Breo ElliptaFluticasone/Vilanterol | 185 | $98,748 |
| Dupixent PenDupilumab | 15 | $53,944 |
| XolairOmalizumab | 19 | $52,273 |
| EliquisApixaban | 136 | $50,110 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 40 | $31,547 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 118 | $21,183 |
| Spiriva RespimatTiotropium Bromide | 26 | $14,601 |
| Advair HfaFluticasone Propion/Salmeterol | 42 | $14,415 |
| SymbicortBudesonide/Formoterol Fumarate | 45 | $13,456 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 45 | $9,080 |
| Montelukast Sodium | 724 | $7,391 |
| MyrbetriqMirabegron | 24 | $6,514 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $28,846 | $324,153495 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $1,539 | $152,74126 claims |
| PfizerEliquis | $576 | $50,110136 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $17,379 | $45,00385 claims |
| Boehringer IngelheimSpiriva Respimat | $106 | $14,60126 claims |
| Hikma Pharmaceuticals USAEpinephrine | $133 | $3,43014 claims |
| AbbVieLumigan | $44 | $2,76612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Gainesville
- Michael MaloneyGainesville$142K
- Kimberley ShanksGainesville$11K
- William NishGainesville$8K
- Amy BoydGainesville$8K
- Faria KhanGainesville$7K
- Nathan SegallStockbridge$4.5M
- Tracy BridgesAlbany$1.5M
- Brad GoodmanSavannah$1.3M
- Michael BlaissRoswell$1.1M
- Robert ChrzanowskiColumbus$941K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.